From the Department of Anesthesiology, Pharmacology and Therapeutics, Uni versity of British Columbia, Vancouver, British Columbia, Canada.
Research Institute, British Columbia Children's Hospital, Vancouver, British Columbia, Canada.
Anesth Analg. 2019 Oct;129(4):1093-1099. doi: 10.1213/ANE.0000000000004154.
Dexmedetomidine is a highly selective α2-adrenergic agonist, which is increasingly used in pediatric anesthesia and intensive care. Potential adverse effects that have not been rigorously evaluated in children include its effects on blood glucose and serum potassium concentrations, which are relevant due to the associations of derangements of both parameters with undesired outcomes. We investigated the effects of 3 different doses of dexmedetomidine on these outcomes in a randomized controlled trial in children undergoing elective surgery.
Sixty-four American Society of Anesthesiologists I-II children were randomized to receive either dexmedetomidine 0.25 µg/kg, dexmedetomidine 0.5 µg/kg, dexmedetomidine 0.75 µg/kg, or 0 µg/kg (control), as a bolus administered over 60 seconds after induction of anesthesia. Changes in plasma glucose and serum potassium concentrations were measured in venous blood sampled before and at 15 and 30 minutes after study drug administration. Data were plotted within and between groups and analyzed using a constrained longitudinal data approach.
Forty-nine children completed the study. Mean glucose levels at 15 and 30 minutes were elevated with estimated changes from baseline of 0.37 mmol/L (95% CI, 0.29-0.45 mmol/L) and 0.05 mmol/L (95% CI, 0.00-0.10 mmol/L), respectively. At 15 minutes, there was a linear dose-response relationship (1.07 mmol/L/μg/kg [95% CI, 0.57-1.58 mmol/L/μg/kg]), but there was no appreciable effect of dexmedetomidine at 30 minutes (0.15 mmol/L/μg/kg [95% CI, -0.40 to 0.70 mmol/L/μg/kg]). Potassium levels were depressed relative to baseline, with a mean difference at 15 minutes of -0.20 mEq/L (95% CI, -0.28 to -0.12 mEq/L) and at 30 minutes of -0.12 mEq/L (95% CI, -0.15 to -0.08 mEq/L), but there was no appreciable effect of dexmedetomidine at either time.
Small elevations in glucose and decreases in potassium were observed after induction of anesthesia in children. The elevation in glucose at 15 minutes depended on the dose of dexmedetomidine administered. These preliminary data warrant further investigation.
右美托咪定是一种高选择性的α2-肾上腺素能激动剂,在小儿麻醉和重症监护中越来越多地使用。尚未在儿童中严格评估的潜在不良反应包括其对血糖和血清钾浓度的影响,由于这两个参数的紊乱与不良结果有关,因此这两种影响都是相关的。我们在一项择期手术的小儿接受的随机对照试验中,研究了 3 种不同剂量的右美托咪定对这些结果的影响。
64 名美国麻醉师协会 I-II 级儿童随机分为接受右美托咪定 0.25μg/kg、右美托咪定 0.5μg/kg、右美托咪定 0.75μg/kg 或 0μg/kg(对照组),在麻醉诱导后 60 秒内推注。在研究药物给药前、给药后 15 分钟和 30 分钟,从静脉血样中测量血浆葡萄糖和血清钾浓度的变化。在组内和组间绘制数据,并使用约束纵向数据方法进行分析。
49 名儿童完成了研究。15 分钟和 30 分钟时的平均血糖水平升高,与基线相比分别升高了 0.37mmol/L(95%置信区间,0.29-0.45mmol/L)和 0.05mmol/L(95%置信区间,0.00-0.10mmol/L)。在 15 分钟时,存在线性剂量反应关系(1.07mmol/L/μg/kg[95%置信区间,0.57-1.58mmol/L/μg/kg]),但在 30 分钟时右美托咪定没有明显影响(0.15mmol/L/μg/kg[95%置信区间,-0.40 至 0.70mmol/L/μg/kg])。与基线相比,钾水平下降,15 分钟时的平均差异为-0.20mEq/L(95%置信区间,-0.28 至-0.12mEq/L),30 分钟时为-0.12mEq/L(95%置信区间,-0.15 至-0.08mEq/L),但在两个时间点右美托咪定都没有明显影响。
在小儿麻醉诱导后观察到血糖升高和血钾降低。15 分钟时的血糖升高取决于给予的右美托咪定剂量。这些初步数据需要进一步研究。